Compass Pathways Phase 3 Psilocybin Trial Shows 3.8-Point MADRS Gain, $150M Offer
Compass Pathways’ Phase 3 COMP006 trial showed a 3.8-point mean MADRS reduction versus a 1 mg control (p<0.001) with 39% response at Week 6 and Day 1 improvement. $150 million public offering at $4.275 per share reflects a 44% discount, injecting commercial cash but diluting existing shareholders.
1. Phase 3 Trial Results
Compass Pathways announced pivotal Phase 3 COMP006 data showing its 25 mg COMP360 dose achieved a 3.8-point mean MADRS reduction versus a 1 mg control (p<0.001), with 39% response at Week 6 and observable improvement by Day 1.
2. Stock Rally and Funding Raise
The clinical win drove a ~33% stock surge on more than 34 million shares traded, but a $150 million public offering at $4.275 per share—a 44% discount—introduced immediate dilution and pre-market pressure before shares resumed their advance.
3. Sector Implications
Compass’s success de-risks the synthetic psilocybin model, validating the mechanism of action for peers like Cybin and Definium Therapeutics and smoothing the regulatory path for other psychedelic therapy developers.
4. Regulatory Pathway and Timeline
With cash runway into 2027, Compass plans a rolling NDA submission in Q4 2026 and will pursue DEA rescheduling post-FDA approval to transition COMP360 from research to episodic clinical treatment.